Please login to the form below

Not currently logged in
Email:
Password:

SHP465

This page shows the latest SHP465 news and features for those working in and with pharma, biotech and healthcare.

Shire claims FDA approval for slow-cooked ADHD drug

Shire claims FDA approval for slow-cooked ADHD drug

Formerly known as SHP465, Mydayis has been approved to treat ADHD in children aged over 13 and adults, as in younger patients it has higher rates of adverse reaction such as

Latest news

  • Shire launches long-acting ADHD drug Intuniv in UK Shire launches long-acting ADHD drug Intuniv in UK

    While Intuniv remains an important ADHD product for Shire, the company's main near-term ambition in the category is securing approval for SHP465, a mixed amphetamine salt product that it

  • Shire pitching at adult ADHD product launch in 2017 Shire pitching at adult ADHD product launch in 2017

    Shire wants to develop a drug called SHP465 (triple-bead mixed amphetamine salts) for adult ADHD, but to satisfy the FDA will have to first carry out a trial of the ... SHP465 will provide 16 hours cover from a single tablet, extending from the morning

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics